Sunesis Announces Proposed Public Offering of Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series C Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.  Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offering for clinical development of SNS-062, regulatory development of vosaroxin in Europe and other general corporate purposes.

Cowen and Company, LLC and Wells Fargo Securities, LLC are acting as Joint Book-Running Managers in these offerings.

The securities described above are being offered by Sunesis pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on June 10, 2014. A preliminary prospectus supplement related to each of the offerings will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov . Copies of the preliminary prospectus supplements and the accompanying prospectus relating to these offerings may be obtained on the SEC's website or from the offices of Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140) or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by email at cmclientsupport@wellsfargo.com , or by telephone at (800) 326-5897.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

For additional information on Sunesis, please visit http://www.sunesis.com .

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the expectations regarding the completion and timing of Sunesis’ proposed offerings. Words such as "may," “intend,” “will,” “potential,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to market conditions and the satisfaction of customary closing conditions related to the proposed offerings. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 and Sunesis' other filings with the Securities and Exchange Commission. There can be no assurance that Sunesis will be able to complete the public offerings on the anticipated terms, or at all. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 16

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 36

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 43

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 78

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 22

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading
Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 31

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
We Are All Human Gala Puts Latino Leadership Center Stage

Updated Category News Views 54

Recognition can sound like soft stuff until a room full of decision-makers decides whose work deserves the microphone. That was the real point of We Are All Human’s sixth annual Gala at Cipriani Wall Street in New York on Nov. 20, 2026: put Latino leadership, cultural influence and economic contribution in plain view rather than treating them as a decorative footnote....

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 0

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of the Nanobiotechnology Market Growth

Updated Category News Views 134

Understanding the Nanobiotechnology Market Trends The nanobiotechnology market has emerged as a rapidly expanding sector, projected to surge from USD 189 billion in 2025 to USD 420.2 billion by 2034, achieving a remarkable CAGR of 9.37% over the forecast period. This growth reflects the increasing integration of nanotechnology in a variety of applications, particularly...

Continue Reading
Transforming a Decade of Investment: The Ensign Group Journey

Updated Category News Views 323

Transforming a Decade of Investment: The Ensign Group Journey Ensign Group (NASDAQ: ENSG) has shown a remarkable performance over the last decade, surpassing the market with an impressive annualized growth rate of 12.64%. This extraordinary growth results in an average annual return of 23.92%, highlighting the potential benefits of long-term investments. Significance of a...

Continue Reading
Chaco Collaborates with Marley Family for Unique Sandals

Updated Category News Views 121

Chaco and Marley Family Unite for a Meaningful Collection Chaco, a premier sandal brand known for its commitment to quality and comfort, has teamed up with the Marley family to create a limited-edition collection inspired by the iconic Bob Marley. This exciting collaboration seeks to embody Marley's legendary message of love, unity, and connection, encouraging wearers to...

Continue Reading
Trump Mobile Launches Game-Changing Wireless Service for All

Updated Category News Views 189

Trump Mobile Launches a Revolutionary Wireless Service In an exciting announcement that aims to reshape the telecommunications landscape, Trump Mobile has introduced its new cellular service called T1 Mobile. This innovative service promises exceptional connectivity and unparalleled value tailored specifically for hardworking Americans. Introducing the 47 Plan for...

Continue Reading
Travel Smart: Unlock the Secrets to Affordable Flights

Updated Category News Views 168

Expedia’s 2025 Air Hacks Report: Unlocking Air Travel Secrets Expedia’s latest report, focusing on air travel hacks, sheds light on the surprising truth about flight pricing. Contrary to popular belief, the peak travel month of July is actually the most affordable time to fly for those leaving from Canadian airports. In fact, travelers can anticipate airfares in July...

Continue Reading